Last reviewed · How we verify
intravitreal ranibizumab & photodynamic therapy
Intravitreal ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor, reducing angiogenesis and edema in the retina.
Intravitreal ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor, reducing angiogenesis and edema in the retina. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion.
At a glance
| Generic name | intravitreal ranibizumab & photodynamic therapy |
|---|---|
| Also known as | Visudyne |
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Anti-VEGF agent |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment that targets VEGF-A, a key mediator of pathological angiogenesis. By binding to VEGF-A, ranibizumab prevents its interaction with its receptor, thereby inhibiting the downstream signaling pathways that lead to angiogenesis and edema. Photodynamic therapy involves the use of a light-sensitive medication and a low-power laser to activate the medication and produce a chemical reaction that destroys abnormal blood vessels in the retina.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion
Common side effects
- Intraocular inflammation
- Increased intraocular pressure
- Endophthalmitis
Key clinical trials
- Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization (PHASE2, PHASE3)
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (PHASE4)
- Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (PHASE1, PHASE2)
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration (PHASE4)
- Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (PHASE4)
- Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
- Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen (NA)
- Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: